Alterations of insulin secretion following long-term manipulation of ATP-sensitive potassium channels by diazoxide and nateglinide

Biochemical Pharmacology

Volumn 69, Issue 1, 2005, Pages 59-63

  Ball, Andrew J ^a,b   Flatt, Peter R ^a   McClenaghan, Neville H ^a  

^a UNIVERSITY OF ULSTER   (United Kingdom)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Clonal pancreatic cells; Diazoxide; Insulin release; K ATP channels; Nateglinide; Tolbutamide

Indexed keywords

1,1 DIMETHYL 2 (2 MORPHOLINOPHENYL)GUANIDINE FUMARATE; ALANINE; AMINO ACID; ARGININE; DIAZOXIDE; FORSKOLIN; GLUCOSE; INSULIN; LEUCINE; NATEGLINIDE; PHORBOL 12 ACETATE 13 MYRISTATE; POTASSIUM CHANNEL STIMULATING AGENT; TOLBUTAMIDE;

ANIMAL CELL; ARTICLE; CELL FUNCTION; CONTROLLED STUDY; INSULIN RELEASE; LONG TERM EXPOSURE; NONHUMAN; PANCREAS ISLET BETA CELL; PHARMACOLOGICAL STIMULATION; PRIORITY JOURNAL; RAT;

ADENOSINE TRIPHOSPHATE; CELL LINE; CYCLOHEXANES; DIAZOXIDE; DRUG ADMINISTRATION SCHEDULE; HUMANS; INSULIN; PHENYLALANINE; POTASSIUM CHANNEL BLOCKERS; POTASSIUM CHANNELS;

EID: 9944242768     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2004.09.009     Document Type: Article

References (26)

1. + channels and insulin secretion: their role in health and disease Diabetologia 42 1999 903 919
2. M.E. Doyle, and J.M. Egan Pharmacological agents that directly modulate insulin secretion Pharmacol Rev 55 2003 105 131
3. A.M. Hansen, I.T. Christensen, J.B. Hansen, R.D. Carr, F.M. Ashcroft, and P. Wahl Differential interactions of nateglinide and repaglinide on the human beta-cell sulphonylurea receptor 1 Diabetes 51 2002 2789 2795
4. N.H. McClenaghan, A.J. Ball, and P.R. Flatt Induced desensitization of the insulinotropic effects of antidiabetic drugs: BTS 67,582 and tolbutamide Br J Pharmacol 130 2000 478 484
5. F.M. Ashcroft, and F.M. Gribble New windows on the mechanism of action of K(ATP) channel openers Trends Pharmacol Sci 21 2000 439 445
6. F.J. Service Insulinoma and other islet-cell tumors Cancer Treat Res 89 1997 335 346
7. M.J. Dunne, K.E. Cosgrove, R.M. Shepherd, A. Aynsley-Green, and K.J. Lindley Hyperinsulinism in infancy: from basic science to clinical disease Physiol Rev 84 2004 239 275
8. A.M. Rabuazzo, M. Buscema, C. Vinci, V. Caltabiano, M. Vetri, and F. Forte Glyburide and tolbutamide induce desensitization of insulin release in rat pancreatic islets by different mechanisms Endocrinology 131 1992 1815 1820
9. J. Kawaki, K. Nagashima, J. Tanaka, T. Miki, M. Miyazaki, and T. Gonoi Unresponsiveness to glibenclamide during chronic treatment induced by reduction of ATP-sensitive K+ channel activity Diabetes 48 1999 2001 2006
10. A.J. Ball, J.T. McCluskey, P.R. Flatt, and N.H. McClenaghan Drug-induced desensitization of insulinotropic actions of sulphonylureas Biochem Biophys Res Commun 271 2000 234 239
11. A.J. Ball, J.T. McCluskey, P.R. Flatt, and N.H. McClenaghan Chronic exposure to tolbutamide and glibenclamide impairs insulin secretion but not transcription of K(ATP) channel components Pharmacol Res 50 2004 41 46
12. J.C. Chapman, N.H. McClenaghan, K.E. Cosgrove, M.N. Hashmi, R.M. Shepherd, and A.N. Giesberts ATP-sensitive potassium channels and efaroxan-induced insulin release in the electrofusion-derived BRIN-BD11 beta cell line Diabetes 48 1999 2349 2357
13. N.H. McClenaghan, A.J. Ball, and P.R. Flatt Specific desensitization of sulphonylurea- but not imidazoline-induced insulin release after prolonged tolbutamide exposure Biochem Pharmacol 61 2001 527 536
14. A.J. Ball, P.R. Flatt, and N.H. McClenaghan Acute and long-term effects of nateglinide on insulin secretory pathways Br J Pharmacol 142 2004 367 373
15. S.H. Song, C.J. Rhodes, J.D. Veldhuis, and P.C. Butler Diazoxide attenuates glucose-induced defects in first-phase insulin release and pulsatile insulin secretion in human islets Endocrinology 144 2003 3399 3405
16. J.L. Leahy, L.M. Bumbalo, and C. Chen Diazoxide causes recovery of beta-cell glucose responsiveness in 90% pancreatectomized diabetic rats Diabetes 43 1994 173 179
17. A. Bjorklund, and V. Grill Enhancing effects of long-term elevated glucose and palmitate on stored and secreted proinsulin-to-insulin ratios in human pancreatic islets Diabetes 48 1999 1409 1414
18. M. Guldstrand, V. Grill, A. Bjorklund, P.E. Lins, and U. Adamson Improved beta cell function after short-term treatment with diazoxide in obese subjects with type 2 diabetes Diabetes Metab 28 2002 448 456
19. N.H. McClenaghan, C.R. Barnett, E. Ah-Sing, Y.H. Abdel-Wahab, F.P. O'Harte, and T.W. Yoon Characterization of a novel glucose-responsive insulin-secreting cell line, BRIN-BD11, produced by electrofusion Diabetes 45 1996 1132 1140
20. P.R. Flatt, and C.J. Bailey Abnormal plasma glucose and insulin responses in heterozygous (ob/+) mice Diabetologia 20 1981 573 577
21. P. Proks, F. Reimann, N. Green, F. Gribble, and F. Ashcroft Sulfonylurea stimulation of insulin secretion Diabetes 51 S3 2002 S368 S376
22. S. Hu, S. Wang, and B.E. Dunning Effectiveness of nateglinide on in vitro insulin secretion from rat pancreatic islets desensitized to sulfonylureas Int J Exp Diabetes Res 2 2001 73 79
23. 2+ Am J Physiol 255 1988 E422 E427
24. J. Levy, and W.J. Malaisse The stimulus-secretion coupling of glucose-induced insulin release-XVII. Effects of sulfonylureas and diazoxide on insular biosynthetic activity Biochem Pharmacol 24 1975 L235 L239
25. G. Skoglund, B. Ahren, and I. Lundquist Biochemical determination of islet lysosomal enzyme activities following crinophagy-stimulating treatment with diazoxide in mice Diabetes Res 6 1987 81 84
26. U. Panten, J. Bergfield, F. Goerke, M. Rennicke, M. Schwanstecher, and A. Wallasch Control of insulin secretion by sulphonylureas, meglitinide and diazoxide in relation to their binding to the sulphonylurea receptor in pancreatic islets Biochem Pharmac 38 1989 1217 1229